HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

PHASE3CompletedINTERVENTIONAL
Enrollment

810

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Asthma
Interventions
DRUG

Fluticasone furoate/Vilanterol Inhalation Powder

Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks

DRUG

Fluticasone propionate/salmeterol Inhalation Powder

Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks

DRUG

Placebo (1)

Inhalation powder inhaled orally once daily for 24 weeks

DRUG

Placebo (2)

Inhalation powder inhaled orally twice daily for 24 weeks

Trial Locations (63)

1000

GSK Investigational Site, Manila

1100

GSK Investigational Site, Quezon City

1425

GSK Investigational Site, Buenos Aires

3019

GSK Investigational Site, Marilao, Bulacan

3100

GSK Investigational Site, Cabanatuan City, Nueva Ecija

4000

GSK Investigational Site, San Miguel de Tucumán

4114

GSK Investigational Site, Dasmariñas, Cavite

6000

GSK Investigational Site, Cebu City

20814

GSK Investigational Site, Bethesda

20902

GSK Investigational Site, Wheaton

27607

GSK Investigational Site, Raleigh

29118

GSK Investigational Site, Orangeburg

29303

GSK Investigational Site, Spartanburg

29615

GSK Investigational Site, Greenville

32927

GSK Investigational Site, Cocoa

45231

GSK Investigational Site, Cincinnati

63141

GSK Investigational Site, St Louis

65401

GSK Investigational Site, Rolla

73103

GSK Investigational Site, Oklahoma City

76712

GSK Investigational Site, Waco

78229

GSK Investigational Site, San Antonio

78750

GSK Investigational Site, Austin

80112

GSK Investigational Site, Centennial

80230

GSK Investigational Site, Denver

90025

GSK Investigational Site, Los Angeles

90048

GSK Investigational Site, Los Angeles

90274

GSK Investigational Site, Rolling Hills Estates

92117

GSK Investigational Site, San Diego

92506

GSK Investigational Site, Riverside

92647

GSK Investigational Site, Huntington Beach

97504

GSK Investigational Site, Medford

2341131

GSK Investigational Site, Valparaíso

2841959

GSK Investigational Site, Rancagua

7500691

GSK Investigational Site, Santiago

7601003

GSK Investigational Site, Santiago

8207257

GSK Investigational Site, Puente Alto - Santiago

08003

GSK Investigational Site, Cherry Hill

08558

GSK Investigational Site, Skillman

C1424BSF

GSK Investigational Site, Buenos Aires

B1878FNR

GSK Investigational Site, Quilmes

E3100BHK

GSK Investigational Site, Paraná

M5500CCG

GSK Investigational Site, Mendoza

S2000DSR

GSK Investigational Site, Rosario

S2000JKR

GSK Investigational Site, Rosario

C1425BEN

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

Unknown

GSK Investigational Site, Viña del Mar

GSK Investigational Site, Santiago

7609 PP

GSK Investigational Site, Almelo

4819 EV

GSK Investigational Site, Breda

3318 AT

GSK Investigational Site, Dordrecht

5623 EJ

GSK Investigational Site, Eindhoven

3844 DG

GSK Investigational Site, Harderwijk

6419 PC

GSK Investigational Site, Heerlen

1624 NP

GSK Investigational Site, Hoorn

5504 DB

GSK Investigational Site, Veldhoven

361-711

GSK Investigational Site, Cheongju, Chungcheongbuk-do

400-711

GSK Investigational Site, Incheon

220-701

GSK Investigational Site, Kangwon-do

110-744

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

443-721

GSK Investigational Site, Suwon, Kyonggi-do

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01147848 - HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents | Biotech Hunter | Biotech Hunter